BioSpace News Archive

Drug Development

Pfizer, Gilead, GSK to Capture Growing Infectious Diseases Market as J&J Pulls Back

The infectious diseases market is expected to reach $150 billion in sales by 2029, with three pharma giants reaping most of its benefits, according to data analytics and consultancy GlobalData.

July 24, 2023
·
2 min read
·
Tristan Manalac
Business

Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension

With an upfront payment of $310 million in cash, Roche is partnering with Alnylam to develop the latter’s RNA interference candidate zilebesiran for hypertension patients with high cardiovascular risk.

July 24, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Kodiak Sciences Scraps Late-Stage Vision Loss Biologic

Company shares fell over 50% after two late-stage studies failed to demonstrate vision improvements in patients with diabetes macular edema.

July 24, 2023
·
2 min read
·
Connor Lynch
Employer Resources

Opinion: The Power of Credibility—How Emerging Biotechs Can Earn Candidates’ Trust

James Ellis, an authority on employer branding for small businesses and biotechs, weighs in on the best ways to earn candidates’ trust.

July 24, 2023
·
5 min read
·
James Ellis
Drug Development

Bavarian Nordic Drops Out of RSV Vaccine Race with Phase III Flop

The Danish vaccine maker’s respiratory syncytial virus candidate did not meet all primary endpoints in a late-stage study in older adults and the company is discontinuing the program.

July 24, 2023
·
2 min read
·
Kate Goodwin
Drug Development

Gilead Ends Late-Stage Trial for Magrolimab in Blood Cancer Treatment

Despite the lifting of the FDA’s partial clinical hold, Gilead will discontinue magrolimab’s development in higher-risk myelodysplastic syndromes after a Phase III study met the bar for futility.

July 24, 2023
·
2 min read
·
Tristan Manalac
Business

Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business

Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results.

July 24, 2023
·
10 min read
Lone Star Bio

Spinal Stabilization Technologies, LLC, a Leading Developer and Manufacturer of Spinal Medical Devices, to be Publicly Listed through a Proposed Business Combination with BlueRiver Acquisition Corp.

Spinal Stabilization Technologies, a medical device company, and BlueRiver Acquisition Corp., a publicly traded special purpose acquisition company, have entered into a definitive business combination agreement.

July 24, 2023
·
12 min read
Business

Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Allarity Therapeutics, Inc. announced the appointment of three seasoned biotechnology executives, Laura Benjamin, Ph.D., Robert Oliver, M.B.A., Joseph Vazzano, C.P.A., to its Board of Directors, effective August 1, 2023.

July 24, 2023
·
10 min read
Drug Development

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease

Belite Bio, Inc announced that enrollment of its pivotal global Phase 3 “DRAGON” trial for patients with Stargardt Disease has completed.

July 24, 2023
·
6 min read